The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its collaboration with China-based Sichuan Clover Biopharmaceuticals to speed-up the development and manufacture of Covid-19 vaccine candidate.
As part of the expanded alliance, CEPI will provide an additional $66m upfront for immediate funding of preclinical studies, to carry out Phase I clinical trials and prepare sites worldwide for an efficacy trial.
Go deeper with GlobalData
The investment will also support scaling up of Clover’s manufacturing capacity to potentially produce millions of doses annually.
